|
Gene: TC2N |
Gene summary for TC2N |
Gene summary. |
Gene information | Species | Human | Gene symbol | TC2N | Gene ID | 123036 |
Gene name | tandem C2 domains, nuclear | |
Gene Alias | C14orf47 | |
Cytomap | 14q32.12 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8N9U0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
123036 | TC2N | LZE5T | Human | Esophagus | ESCC | 1.08e-12 | 1.12e+00 | 0.0514 |
123036 | TC2N | LZE8T | Human | Esophagus | ESCC | 6.74e-04 | 8.71e-02 | 0.067 |
123036 | TC2N | LZE20T | Human | Esophagus | ESCC | 5.26e-15 | 6.29e-01 | 0.0662 |
123036 | TC2N | LZE22T | Human | Esophagus | ESCC | 2.17e-06 | 2.11e-01 | 0.068 |
123036 | TC2N | LZE24T | Human | Esophagus | ESCC | 1.46e-24 | 7.94e-01 | 0.0596 |
123036 | TC2N | P1T-E | Human | Esophagus | ESCC | 3.84e-11 | 7.08e-01 | 0.0875 |
123036 | TC2N | P4T-E | Human | Esophagus | ESCC | 4.93e-02 | -9.06e-02 | 0.1323 |
123036 | TC2N | P5T-E | Human | Esophagus | ESCC | 2.53e-04 | -1.29e-01 | 0.1327 |
123036 | TC2N | P8T-E | Human | Esophagus | ESCC | 4.17e-31 | 6.73e-01 | 0.0889 |
123036 | TC2N | P9T-E | Human | Esophagus | ESCC | 3.12e-06 | 5.61e-02 | 0.1131 |
123036 | TC2N | P10T-E | Human | Esophagus | ESCC | 8.32e-31 | 5.65e-01 | 0.116 |
123036 | TC2N | P15T-E | Human | Esophagus | ESCC | 1.83e-28 | 7.19e-01 | 0.1149 |
123036 | TC2N | P17T-E | Human | Esophagus | ESCC | 2.46e-02 | 3.18e-01 | 0.1278 |
123036 | TC2N | P20T-E | Human | Esophagus | ESCC | 4.14e-13 | 2.60e-01 | 0.1124 |
123036 | TC2N | P22T-E | Human | Esophagus | ESCC | 1.14e-10 | 3.18e-02 | 0.1236 |
123036 | TC2N | P23T-E | Human | Esophagus | ESCC | 1.60e-20 | 5.00e-01 | 0.108 |
123036 | TC2N | P24T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.97e-02 | 0.1287 |
123036 | TC2N | P26T-E | Human | Esophagus | ESCC | 3.39e-18 | 1.06e-01 | 0.1276 |
123036 | TC2N | P27T-E | Human | Esophagus | ESCC | 6.90e-06 | 8.19e-02 | 0.1055 |
123036 | TC2N | P28T-E | Human | Esophagus | ESCC | 2.05e-17 | 4.16e-01 | 0.1149 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TC2N | SNV | Missense_Mutation | c.596C>G | p.Ser199Cys | p.S199C | Q8N9U0 | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
TC2N | SNV | Missense_Mutation | rs773399002 | c.595T>A | p.Ser199Thr | p.S199T | Q8N9U0 | protein_coding | tolerated(0.73) | benign(0.001) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
TC2N | SNV | Missense_Mutation | c.180N>A | p.Asp60Glu | p.D60E | Q8N9U0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
TC2N | SNV | Missense_Mutation | c.247T>C | p.Ser83Pro | p.S83P | Q8N9U0 | protein_coding | deleterious(0) | benign(0.373) | TCGA-BH-A0EA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | CR | |
TC2N | SNV | Missense_Mutation | c.419N>G | p.Leu140Trp | p.L140W | Q8N9U0 | protein_coding | tolerated(0.05) | possibly_damaging(0.594) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
TC2N | SNV | Missense_Mutation | c.390C>G | p.Phe130Leu | p.F130L | Q8N9U0 | protein_coding | tolerated(0.66) | benign(0.003) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
TC2N | SNV | Missense_Mutation | rs759393076 | c.1041A>C | p.Lys347Asn | p.K347N | Q8N9U0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TC2N | SNV | Missense_Mutation | c.428G>A | p.Arg143His | p.R143H | Q8N9U0 | protein_coding | deleterious(0) | possibly_damaging(0.513) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
TC2N | SNV | Missense_Mutation | c.1045T>C | p.Ser349Pro | p.S349P | Q8N9U0 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TC2N | SNV | Missense_Mutation | c.1306N>G | p.Phe436Val | p.F436V | Q8N9U0 | protein_coding | deleterious(0.01) | possibly_damaging(0.824) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |